Across Asia, pharma leaders are working hard to accelerate their Industry 4.0 digital transformation and, in the process, ensure current Good Practice (cGXP) compliance. IDC analysts found Asia’s digital transformation is accelerating in response to post-pandemic market dynamics. How can Asia’s drug manufacturers throttle up digitisation efforts effectively? Kenneth Teo at Cognizant offers insight into IDC findings as well as fresh strategies on how the region’s leaders can improve operations by adopting digital technologies.